Skip to content
OpenCapital
Get started

Edgewise Therapeutics, Inc. EWTX Payments Of Debt Issuance Costs

Payments Of Debt Issuance Costs at other companies

Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
——
Scholar Rock logo
Scholar RockSRRK
——
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
——
Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.18B+61.3%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0×0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s payments of debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s payments of debt issuance costs?
Edgewise Therapeutics, Inc. (EWTX) reported payments of debt issuance costs of $38K in Q1 2025.